Russian scientists say Sputnik V performs well against COVID mutations


FILE PHOTO: A medical specialist holds a vial of Sputnik V vaccine against the coronavirus in a department store in Moscow, Russia, January 18, 2021 REUTERS/Shamil Zhumatov/File Photo

MOSCOW (Reuters) - A Russian trial testing the effectiveness of revaccination with the Sputnik V shot to protect against new mutations of the coronavirus is producing strong results, researchers said on Saturday.

Last month President Vladimir Putin ordered a review by March 15 of Russian-produced vaccines for their effectiveness against new variants spreading in different parts of the world.

"(A) recent study carried out by the Gamaleya Centre in Russia showed that revaccination with Sputnik V vaccine is working very well against new coronavirus mutations, including the UK and South African strains of coronavirus," said Denis Logunov, a deputy director of the centre, which developed the Sputnik V shot.

Results of the trial are expected to be published soon, but this was the first indication of how the tests are going. No further details were available yet.

So-called viral vector shots - such as Sputnik V and a shot developed by AstraZeneca - use harmless modified viruses as vehicles, or vectors, to carry genetic information that helps the body build immunity against future infections.

The revaccination used the same Sputnik V shot, based upon the same adenovirus vectors. The trial indicated this did not impact effectiveness, Logunov said in a statement to Reuters.

Some scientists have raised the possible risk that the body also develops immunity to the vector itself, recognising it as an intruder and trying to destroy it.

But developers of Sputnik V disagreed this would pose long-term problems.

"We believe that vector-based vaccines are actually better for future revaccinations than vaccines based on other platforms," Logunov said.

He said that the researchers found that antibodies specific to the vectors used by the shot - which could generate an anti-vector reaction and undermine the work of the shot itself - waned "as early as 56 days after vaccination".

This conclusion was based on a trial of a vaccine against Ebola developed earlier by the Gamaleya Institute using the same approach as for the Sputnik V shot.

Vector immunity is not a new issue but has come under renewed scrutiny as companies including Johnson & Johnson anticipate regular COVID-19 vaccinations, like annual influenza shots, may be needed to combat new variants of the coronavirus.

(Reporting and writing by Polina Ivanova; Editing by Frances Kerry)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In World

'You can't clone us': Polish doctors cry for help as COVID deaths spike
Pentagon team reveals Covid-19-detecting chip that can be implanted in the body
Opponents of Myanmar coup announce unity government
Sweden eases restrictions on people who have had COVID vaccination
Merkel says lockdowns, curfews vital to break Germany's third wave
UK's Frost says positive momentum in EU talks, difficult issues remain
Britain must act jointly with EU on Northern Ireland - EU's Sefcovic
Opponents of Myanmar's junta set up national unity government
'Mass casualty' shooting reported in US city of Indianapolis, gunman dead, say police
Denmark speeds up reopening as epidemic stabilises

Stories You'll Enjoy


Vouchers